Ratings Carl Zeiss Meditec AG London S.E.

Equities

0DHC

DE0005313704

Real-time Estimate Tradegate Other stock markets 04:34:45 2024-05-14 EDT			5-day change	1st Jan Change
94.18 ^EUR	+1.02%		-5.44%	-4.90%

05-10	CARL ZEISS MEDITEC AG : Hauck & Aufhauser gives a Buy rating	ZD
05-09	CARL ZEISS MEDITEC AG : Deutsche Bank sticks Neutral	ZD

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Over the past four months, analysts' average price target has been revised upwards significantly.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.78 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 3.94 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
CARL ZEISS MEDITEC AG	-4.90%	8.98B	-
THERMO FISHER SCIENTIFIC	+11.29%	225B	B
DANAHER CORPORATION	+8.76%	186B	B-
INTUITIVE SURGICAL, INC.	+12.90%	135B	B-
BOSTON SCIENTIFIC CORPORATION	+25.95%	107B	A-
SIEMENS HEALTHINEERS AG	+0.27%	63.56B	A-
EDWARDS LIFESCIENCES CORPORATION	+11.08%	51.04B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.62%	51.32B	B+
AGILENT TECHNOLOGIES, INC.	+6.28%	43.3B	A
GE HEALTHCARE TECHNOLOGIES INC.	+4.80%	36.99B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes